AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 131 min read$LQDA

Adair Jason sold $208K of LQDA

Adair Jason (Chief Business Officer) sold 7,301 shares of Liquidia Corp (LQDA) at $28.48 ($0.21M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Adair Jason
Published Oct 13, 2026, 11:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
high confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The transaction reduces the insider's stake and could be interpreted as reduced confidence, prompting short‑term price pressure.

02

Market read

A modest insider sale that may cause short‑term downside but is unlikely to move the broader market.

03

What to watch

Potential upcoming financing or strategic moves not disclosed.

Relevance 3/10Novelty 3/10Timing: post‑market today

Background

Form 4 filing provides the first public disclosure of the insider's share sale.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Chief Business Officer sold 7,301 shares for $207,932.48 on 2026-10-12 via a 10b5‑1 plan.

Expected impact

likely downward pressure as the market prices the insider sell.

Evidence & confidence

The sale is sizable relative to the insider's holdings and was executed through an open‑market transaction.

Market effects

Sector

Minimal impact on the biotech sector; isolated insider activity.

Regional

No broader regional effect.

Global

Limited to investors tracking Liquidia.

Counterpoint

What could challenge this read

The sale may be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Liquidia Corp

    Biotech company listed on NASDAQ under ticker LQDA.

  • Executive
    Adair Jason

    Chief Business Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min